Drug Trial Radar · NCT00563368
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Last checked: Nov 19, 2026Latest source record: Mar 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
756
Actual
Start
Dec 2007
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Nov 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
Conditions
- Obesity
Interventions
VI-0521Drug
phentermine 15 mg and topiramate 92 mg, po once daily
VI-0521Drug
phentermine 7.5 mg and topiramate 46 mg, po once daily
topiramateDrug
topiramate 46 mg, po once daily
topiramateDrug
topiramate 92 mg, po once daily
phentermineDrug
phentermine 7.5 mg, po once daily
phentermineDrug
phentermine 15 mg, po once daily
VI-0521Drug
placebo, po once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Weight Loss From Baseline to Week 28Time frame: baseline to 28 weeks
- Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCFTime frame: baseline to 28 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Durham, North Carolina
Research Site
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.